65,437 trials
Classic Hodgkin Lymphoma · Lugano Classification Stage III Hodgkin Lymphoma AJCC v8 · Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
Primary: Event-free Survival (EFS) Rate — 17; 20 Participants
Healthy
Primary: Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 16 Days After…
Acute Myeloid Leukemia (AML)
Primary: Overall Survival (OS) — 4.1; 7.2 months — p=0.114
Devic's Disease
Primary: Survival — 13; 12; 12; 11 Participants
Recurrent Epithelial Ovarian Cancer · Recurrent Fallopian Tube Cancer · Recurrent Primary Peritoneal Cancer
Primary: Overall Response Rate (ORR) — 4 participants
Schizophrenia Spectrum & Other Psychotic Disorders
Primary: Provision of Appropriate Preventive and Medical Treatments — 144; 117; 146; 131 Participants
Renal Impairment · Healthy
Primary: Cmax — 545.4; 593.2; 475.9 ng/mL
Obsessive-Compulsive Disorder
Primary: Change in Yale-Brown Obsessive Compulsive Scale — 24.0; 14.2; 2.5; 11.2 score on a scale
Bipolar Disorder
Primary: MATRICS Consensus Cognitive Battery — 35.45; 38.07 T-score — p=0.38
Complications; Cesarean Section
Primary: Incision Time . — 271.5; 188.17 Seconds — p=<0.001
Stroke · CVA · Hemiplegia
Primary: Gait Endurance — 203.44; 195.15 Meter — p=.293
Colorectal Adenocarcinoma · RAS Wild Type · Stage IV Colorectal Cancer AJCC v7
Primary: Progression-Free Survival (PFS) — 9.7; 5.5 months — p=0.7609
Systemic Lupus Erythematosus
Primary: Survival — 28; 2; 28; 0 Participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c: Week 26 — -0.6; -1.1; -1.3; -0.8 Percentage of HbA1c — p=< 0.0001
Arteriovenous Fistula Stenosis · Arteriovenous Fistula Occlusion · Arteriovenous Fistula
Primary: Target Lesion Primary Patency Rate Through 6 Months — 125; 88 Participants — p=<0.001